Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05266898 · ClinicalTrials.gov registry record · Phase 4
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
A Phase 4 study of Human Immunodeficiency Virus and Cervical Intraepithelial Neoplasia, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT05266898 is a Phase 4 study of Human Immunodeficiency Virus and Cervical Intraepithelial Neoplasia that is actively recruiting participants, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 250 participants, above the 178-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (40% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05266898, a Phase 4 study of Human Immunodeficiency Virus and Cervical Intraepithelial Neoplasia, is actively recruiting participants, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection. The secondary objectives of the study are to observe short term clinical outcomes of prevalent HPV genotype-specific anogenital infections in adults living with HIV who complete the three-dose Gardasil-9 vaccine series, and to determine the protection afforded by Gardasil vaccine over time in previously vaccinated adults living with HIV. The clinical hypothesis is that adults with virologically controlled HIV mount a serum antibody response to the nonavalent HPV vaccine that is comparable to HIV negative counterparts. We also postulate that HPV vaccination will provide short-term clinical benefit against HPV infections and disease associated with vaccine genotypes and continuing protection against vaccine genotypes of HPV over time.
Conditions Studied
Interventions
- BIOLOGICAL Human papillomavirus 9-valent vaccine, recombinant
- BIOLOGICAL human papillomavirus vaccine, recombinant
Study Locations (1)
Louisiana
- University Medical Center New Orleans - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05266898
The ClinicalTrials.gov registry entry for NCT05266898 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 178-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (40% higher). The listed sponsor is Louisiana State University Health Sciences Center in New Orleans, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 2 interventions - of which Human papillomavirus 9-valent vaccine, recombinant is the first listed.
NCT05266898 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT05266898 about?
NCT05266898 is a clinical study titled "Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV". The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection. The secondary objectives of the study are to observe short term clinical outcomes of prevalent HPV ge...
What is the current status of trial NCT05266898?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2022-11-30. Estimated completion is 2026-06.
What conditions does trial NCT05266898 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus, Cervical Intraepithelial Neoplasia, Papillomavirus Vaccines, Papillomavirus Infection, Serology.
What interventions are being tested in trial NCT05266898?
The interventions under investigation include: Human papillomavirus 9-valent vaccine, recombinant (BIOLOGICAL), human papillomavirus vaccine, recombinant (BIOLOGICAL).
Who is sponsoring clinical trial NCT05266898?
This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05266898 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Dose Naltrexone for Pain in Patients With HIV
RECRUITING · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Post-Exposure Prophylaxis in Health Care Workers
COMPLETED · Phase 4
-
Biomarkers for Event-driven PrEP Adherence
COMPLETED · Phase 4
-
Switching Undetectables to Selzentry
COMPLETED · Phase 4
-
HIV Non-Occupational Post-Exposure Prophylaxis
COMPLETED · Phase 4
Explore more on PlainTrial
Human Immunodeficiency Virus
All registered trials for this condition
Cervical Intraepithelial Neoplasia
All registered trials for this condition
Louisiana
All trials with a study site in Louisiana
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.